Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGGS34 in Advanced Solid Tumors
NCT07258121Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ZGGS34 in solid tumor, gastric cancer (GC), pancreatic cancer (PC), colorectal cancer (CRC), sponsored by Zelgen. Started Dec 2025; status: recruiting.
02
Drugs
ZGGS34
03
Conditions
solid tumorgastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07258121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258121.